← Sazabi Research

GE HealthCare — Record Orders, Quiet Turnaround

GEHC (NASDAQ) — Quick Take

📅 July 30, 2026 Healthcare MedTech AI Imaging NASDAQ
Market Cap
$32.8B
Revenue (TTM)
$21.2B
P/E (Fwd)
14.7x
Rev Growth
+5.8%

Why This Company Now

GE HealthCare surged +12.2% on July 30 after reporting Q2 2026 earnings that crushed expectations — $5.30B revenue (+5.8% YoY) and adjusted EPS of $1.13 both cleared consensus. Healthcare dominated today's US VolumeSurge screener with 14 stocks surging on volume, and GEHC was the #1 pick by turnover. The move is backed by record orders (+11.1% organic), a record $23.9B backlog, and a 1.15x book-to-bill ratio that provides exceptional revenue visibility into 2027. With the $2.3B Intelerad cloud-imaging acquisition now closed and management reviewing strategic options for the underperforming Patient Care Solutions division, GEHC has multiple catalysts beyond the earnings beat.

Financial Snapshot

YearRevenueRev GrowthAdj. EBIT MarginNet Income
FY2023 $19.55B — 15.1% $1.56B
FY2024 $19.67B +0.6% 16.3% $1.99B
FY2025 $20.63B +4.8% 15.3% $2.08B
FY2026E ~$21.5B +4.2% 15.4–15.7% ~$2.25B

FY2026 figures are management guidance midpoint. Revenue includes contribution from Intelerad acquisition (closed March 2026). TTM revenue as of Q2 2026 is approximately $21.2B.

Bull vs Bear

✅ Bull Case

  • Record backlog = earnings visibility. $23.9B backlog (+$2.6B YoY) and 1.15x book-to-bill ratio mean the next 4–6 quarters of revenue are substantially pre-sold. Orders growing 3× faster than revenue — the flywheel is accelerating.
  • Intelerad opens a cloud-imaging TAM. The $2.3B acquisition of Intelerad (closed March 2026) combines GEHC's AI imaging expertise with a cloud-native radiology workflow platform. This creates a recurring-revenue software layer on top of the hardware install base and expands the addressable market meaningfully.
  • Patient Care Solutions optionality. Management is formally reviewing strategic options for the PCS division (declining 13.3% in Q2). A sale or spin could unlock $3–5B in value while removing a drag on margins and growth optics. At 14.7× forward P/E, the market is not pricing in any breakup value.

🔴 Bear Case

  • Low-single-digit organic growth is the ceiling. Organic revenue grew just 3.5% in Q2 and is guided to 3–4% for the full year. This is a mature, capital-equipment-heavy business — hospital CapEx cycles determine growth, not product innovation alone.
  • Margin headwinds are structural, not cyclical. $250M in persistent inflation costs (memory chips, oil, freight) plus tariffs are compressing adjusted EBIT margins to 15.4–15.7%, well below the 16.3% achieved in FY2024. The Intelerad integration adds execution risk before it adds accretion.
  • CFO departure during a complex integration. Jay Saccaro, CFO since the 2023 spin-off, leaves August 14 — right as GEHC digests its largest-ever acquisition. Interim CFO George Newcomb is capable but untested in the seat. Leadership churn at this juncture raises the risk of mis-execution.

Verdict

GE HealthCare is executing a quiet turnaround that the market is just starting to notice. The record orders and backlog provide rare visibility in medtech, and the Intelerad deal is a smart move into higher-margin cloud software. The Patient Care Solutions strategic review is a legitimate catalyst — a divestiture would simultaneously remove a growth drag, boost margins, and return capital. The 14.7× forward P/E is cheap for a business with this much contractual revenue visibility, even with the low organic growth rate. The CFO departure and inflation headwinds are real risks, but at this valuation, the risk/reward tilts favorable if you believe management can execute on the Intelerad integration and PCS resolution over the next 12 months.

Disclaimer: AI-generated quick take for informational purposes only. Not investment advice. Data from public filings and financial data providers. Revenue and earnings figures sourced from GE HealthCare investor relations, SEC filings, and consensus estimates.